Gate Crypto Flash News and Market Updates

Gate Flash News covers real-time crypto market updates, Bitcoin and Ethereum price movements, and key industry developments.
Today
10:16
0

Stone Pharma (01093) Launches Phase I Trial for SYH2083 Eye Drops in Dry Eye Disease

According to Stone Pharma (01093), the company announced today that SYH2083 eye drops, a dual-target LFA-1/RASP inhibitor, has initiated a Phase I clinical trial (SYH2083-001) for dry eye disease in China. The single-center, randomized, double-blind, placebo-controlled dose-escalation trial aims to evaluate safety, tolerability, and pharmacokinetics in healthy volunteers. Participant recruitment and screening are currently underway.
10:15
0

FINMA Approves Switzerland's First Retail Bitcoin ETF With Special Risk Designation

According to ChainCatcher, the Swiss Financial Market Supervisory Authority (FINMA) approved the country's first retail-focused Bitcoin ETF. The product is classified as an alternative investment fund under Swiss law and designated as carrying special risk. FINMA did not disclose the issuer but multiple outlets reported signs indicating the fund may come from BIT Asset Management. As a single-asset fund, it invests entirely in Bitcoin, requiring FINMA to grant an exemption from its diversificati
More
10:13
0

Intel Eyes Nvidia Collaboration Signals at Berlin GTC 2026 on Oct 21

According to tech media Wccftech, Intel is awaiting confirmation from Nvidia regarding extended processor partnerships, potential foundry services, and advanced packaging collaboration at the Berlin GTC conference beginning October 21. The analysis highlights three potential opportunities for Intel: continuing as a CPU supplier for Nvidia's next-generation DGX systems (currently using Xeon 6776P), providing foundry services for Feynman-generation I/O chiplets using Intel's 18A-P or 14A processes
More
10:11
0

Huahao Zhongtian Pharmaceutical Initiates Phase III Trial of Utidelone Capsule for HER2-Negative Advanced Breast Cancer

According to Huahao Zhongtian Pharmaceutical, its oral utidelone capsule (UTD2) achieved first patient dosing today in a Phase III clinical trial (BG02-2601) for HER2-negative advanced breast cancer, marking the global first oral microtubule stabilizer key registration trial. The randomized, controlled trial compares utidelone capsule combined with capecitabine (CAP) against the marketed intravenous utidelone injection (UTD1) plus CAP in patients previously treated with taxanes or anthracyclines
More
10:11
0

China Tower Posts RMB 10.817 Billion Net Profit in First Three Quarters, Up 24.2% YoY

According to China Tower (00788), in the first three quarters of 2026, the company's net profit attributable to shareholders reached RMB 10.817 billion, up 24.2% year-over-year. Operating revenue was RMB 71.999 billion, down 3.1% from the prior year, with telecommunications operator business revenue declining 6.0% to RMB 59.641 billion, offset by smart linkage business revenue rising 10.9% to RMB 7.869 billion and energy business revenue growing 13.0% to RMB 3.868 billion. The combined revenue c
More
10:07
0

Bitget Plans to Acquire Thai Crypto Exchange GMO-Z.com on October 20

According to Bitget, on October 20, the Seychelles-based exchange announced plans to acquire GMO-Z.com Cryptonomics (Thailand) Co Ltd through its interest in BTGT Management (Thailand) Ltd. Under the proposed transaction, Japan's GMO Internet Inc and other shareholders would transfer their entire stakes to BTGT Management (Thailand) Ltd and/or its designated entity. Completion is subject to regulatory approval from Thailand's Securities and Exchange Commission (SEC) and other conditions. Bitget
More
10:07
0

Baoji Pharma-B's BJ045 Injection Receives IND Approval from China's NMPA on October 19

According to Baoji Pharma-B's announcement, the company's self-developed BJ045 subcutaneous injection, a CD20 monoclonal antibody, received clinical trial approval (IND) from China's National Medical Products Administration (NMPA) on October 19, 2026. The approval permits BJ045 to proceed with clinical trials in China. BJ045 is designed as a subcutaneous anti-CD20 antibody with potential to be combined with IgG-degrading enzyme therapies (such as the company's KJ103) for treating moderate to sev
More
10:06
0

Northbound Investors Record HKD 17.23 Billion Net Outflows on October 20; Tencent Receives HKD 11.47 Billion Net Inflows

According to Zhitong Finance, on October 20, Northbound investors achieved net outflows of HKD 17.23 billion in Hong Kong stocks. The Shanghai-Hong Kong Connect recorded net outflows of HKD 8.49 billion, while the Shenzhen-Hong Kong Connect saw net outflows of HKD 8.74 billion. Tencent Holdings (00700) received the largest net inflows among Northbound-tracked stocks at HKD 11.47 billion, followed by China National Offshore Oil Corporation (00883) with HKD 2.74 billion and MINIMAX-W (00100) with
More
10:01
0

U.S. Fintech Meow Raises $31.6M in Series B Led by Stifel

According to Foresight News, U.S. fintech company Meow completed a $31.6 million Series B funding round led by Stifel, with Archetype VC participating. Stifel plans to offer a white-label version of Meow's platform to its commercial banking clients, initially targeting venture capital and fund banking services, with launch expected in early 2027. The company has previously partnered with Stripe, Bridge, and Tempo on stablecoin initiatives.
10:01
0

OpenAI and Meta Warn of Deepfake Threat to Legal Evidence on October 15

According to Reuters, OpenAI and Meta representatives warned on October 15 at a U.S. judicial conference that AI-driven deepfakes pose a serious threat to evidence reliability in legal proceedings. OpenAI policy advisor Shira Anderson stated that AI-generated images are rapidly improving in quality and may become indistinguishable from authentic media in the future. Meta product management director Devin Norder added that humans can no longer reliably distinguish real media from content generate
More
10:01
0

ZEALER Founder Unveils VIVA AI Health Management Product With Three Virtual Roles

According to ChainCatcher, ZEALER founder Wang Ziyu unveiled VIVA, his first AI product focused on personal health management. The app integrates three virtual roles—a nutritionist, fitness coach, and life assistant—within a single chat interface that share conversation context. Users can photograph meals or describe their food intake, allowing the AI to estimate calories and track nutritional data. The fitness coach schedules workouts, provides guidance, and logs progress, while the life assist
More
10:00
0

Binance Adjusts Leverage and Margin Tiers for 15 USDT-M Perpetual Contracts by October 30

According to Binance, the exchange will adjust leverages and margin tiers for 15 USDT-M perpetual contracts by October 30, 2:30 PM UTC+8. The affected contracts include APRUSDT, AIOUSDT, TRIAUSDT, WETUSDT, STBLUSDT, IDOLUSDT, GOATUSDT, QUSDT, B2USDT, AIAUSDT, CYSUSDT, DOSUSDT, TURTLEUSDT, AVAAIUSDT, and TRADOORUSDT. Existing open positions prior to the update will be affected by the changes.
10:00
0

UBTech Establishes Embodied AI Subsidiary in Huizhou With 20M Yuan Registered Capital

According to PANews on October 20, UBTech subsidiary Huizhou Guanfu Embodied AI Technology Co., Ltd. was established with registered capital of 20 million yuan. The company is fully owned by UBTech, a Hong Kong-listed firm. Its business scope includes AI application software development and intelligent robotics research and development.
09:56
0

XYZprinting Launches SPARKX i8 Multi-Color 3D Printer in China at 2,509 Yuan; Crowdfunding Hits $4.63M

According to Zhitong Finance, on October 20, XYZprinting (03388) opened presales for its SPARKX i8 multi-color 3D printer in China at 2,509 yuan (approximately $347), with promotional pricing potentially dropping to 2,199 yuan during the Alibaba Double Eleven shopping festival. The device previously exceeded $4.63 million in crowdfunding on Indiegogo with over 10,000 backers, setting multiple records in the platform's 3D printing category. Equipped with the company's proprietary QuarTeks four-ch
More